2018
PRESENTATION

REGENERAGE®
CLINIC
INNOVATIVE ANTI-AGING SOLUTIONS

RegenerAge® Clinic © 2018
www.regenerage.clinic


REGENERAGE® OFFERS YOU A WIDE PORTFOLIO OF

REGENERATIVE TREATMENTS

With the goal of promoting optimal health, RegenerAge offers cutting edge regenerative medicine treatments to achieve regeneration, repair and rejuvenation of your entire body.



RegenerAge® Clinic © 2018
www.regenerage.clinic



WELCOME TO THE REGENERAGE® SYSTEM

The Future of Human Regeneration, Repair and Rejuvenation

To achieve a transformational level of **technological advancement** in the regenerative **medical** area for humans, RegenerAge® is utilizing *novel* combination applications of **biological interventions**, including **stem cells**, **soluble regenerative biologics**, ***proprietary*** **nutritional bio-products**, **functional** and **regenerative** based diets, **bioidentical hormone replacement**, and **skin** / aesthetic **rejuvenation** tools, yielding an unprecedented option for activating the **natural healing processes** of the body and **maintaining health** and **wellness**.

RegenerAge® Clinic © 2018
www.regenerage.clinic

REGENERAGE®

✓ “NO OPTION” PATIENT - CLINICAL TRIAL GAPS


Major clinical trial gaps currently exist across all therapeutic segments that are responsible for human suffering and death. Cancer is one prime example. As a leading cause of morbidity and mortality worldwide for many decades, today there are approximately 14 million new cases diagnosed each year, with over 8 million cancer related deaths annually (patients who become 'no option'). It is estimated that less than 5% of these patients, take the initiative to participate in any available clinical studies, partially due to the substantial complexity involved with accessing current experimental programs of the industry.

✓ COMPASSIONATE CLINICAL USE


As part of its business model, RegenerAge will capitalize on expedited, experimental access for 'no option' patients around the globe. We define a 'no option' patient as any patient, with any serious medical condition, where existing standard-of-care treatment has been exhausted, who has been designated as 'end-stage' or 'terminal', who will endure needless suffering and death without further interventions, and where effective, experimental treatments may exist outside of their present sphere of care access. RegenerAge plans to take advantage of the substantial patient demand for experimental therapies, with the growing dynamics of the procedural medical travel market, integrating novel clinical development models, geographic regulatory advantages, and creative legislative initiatives to accomplish its goal, all with rigorous scientific standardization and oversight.

✓ PROCEDURAL MEDICAL TRAVEL

The estimate of the current market size for procedural medical travel, defined by medical travelers who travel across international borders for the purpose of receiving medical care, is in the range of US $40-55 billion, based on approximately eleven million cross-border patients worldwide spending an average of USD 3,500-5,000 per visit, including all medically-related costs, cross-border and local transport, inpatient stay and accommodations. It is estimated that currently over a million Americans travel outside the US for medical annually. As the world population is aging and becoming more affluent at rates that surpass the availability of quality healthcare resources, out-of-pocket medical costs of critical and elective procedures will continue to rise, while nations offering universal care are faced with ever-increasing resource burdens.



RegenerAge® Clinic © 2018
www.regenerage.clinic



✓ **COMBINATORIAL BIOLOGICS -** BIOQUANTINE®

BQ-A® is a **novel biological complex** that mimics the **regulatory biochemistry** of living **human zygote** (oocyte) immediately **after fertilization**. During this period, **oocytes** undertake an unprecedented set of tasks that include: **restoring cellular age**, **reprogramming DNA** to **eliminate genetic and epigenetic damage**, **remodeling of organelles**, and **protection of the embryo** from **inflammatory**, **oxidative** or **infectious factors**. All this is done in **synergy** to start the *genetic program of embryo development*, and start it on its complex pathway, step by step through **organogenesis** and **morphogenesis**. **Bioquark, Inc.®** has found a new way to standardize this unique biochemical complex as a **therapeutic derivative**, thereby generating **induction of specific tissues micro-environments** *conducive* to **regeneration** and **cellular repair**. **Bioquark, Inc.®** is the **first company** that has taken the step to export this natural architecture of the *biochemical regulation to diseased tissues in humans*.

RegenerAge® Clinic © 2018
www.regenerage.clinic



COMBINATORIAL BIOLOGICS

REGENERAGE®
CLINIC
INNOVATIVE ANTI-AGING SOLUTIONS

RegenerAge® Clinic © 2018
www.regenerage.clinic
info@regenerage.clinic




Bioquark Inc.®

NEXT-GENERATION THERAPEUTICS FOR HUMAN
REPAIR & REGENERATION

Bioquark® BQ-A® © 2018
www.bioquark.com

COMBINATORIAL BIOLOGICS



Bioquark Inc.®

COMBINATORIAL BIOLOGICS (BIOQUANTINE®)


Bioquark Inc.®, a commercial and strategic partner of RegenerAge®, designed and **patented** the process for obtaining (**BQ-A®**), containing over **90 polypeptides** (proteins used to *repair damaged human DNA and cells*) which can be applied **therapeutically** to a wide range of patients in an advanced state of **cellular damage and illness**. Working at many **molecular levels**, and combined with other treatments, may potentiate and synergize expanded **regenerative benefits**.

RegenerAge® Clinic © 2018
www.regenerage.clinic


REGENERAGE®


COMBINATORIAL BIOLOGICS

DNA Reprogramming




Organism Viral Extinction






Organelle Remodelling



Cell Competition Induction



Targeted Tissue Histolysis



Organ/Organ Systems


Induction of Endogenous
Innate Regenerative Mechanisms



RegenerAge® Clinic © 2018
www.regenerage.clinic

REGENERAGE®


REPROGRAMMING MEDICINE



REGENERAGE®
CLINIC
INNOVATIVE ANTI-AGING SOLUTIONS

RegenerAge® Clinic © 2018
www.regenerage.clinic

BACKGROUND



REPROGRAMMING-BASED MEDICINE

The ability to **endogenously repair or regenerate** *human cells, tissues, organs, and even limbs, to restore or establish normal function*, holds the promise to **substantially impact** on the most dreaded **ailments** responsible for **human disease**, **degeneration**, and **death**. However, humans beings are mostly devoid of any such natural capabilities.

Fortunately, there are many members of the biologic kingdom that do possess such capabilities in a robust and reproducible manner throughout their lifespans (and some which even use them to **extend their lifespans**).

Our **clinical program** is focused on **medical applications** for patients who want to receive a natural **biologic therapy** to 'restart' their *cellular reprogramming*, and then translate these applications into therapeutic cures for human beings.

RegenerAge® Clinic © 2018
www.regenerage.clinic

REGENERATIVE PROPERTIES

RECONSTRUCTING FUNCTION

BQ-A® is a novel biological complex that mimics the regulatory biochemistry of living human zygote (oocyte) immediately after fertilization. During this period, oocytes undertake an unprecedented set of tasks that include: **restoring cellular age**, **reprogramming DNA** to *eliminate genetic and epigenetic damage*, **remodelling of organelles**, and **protection of the embryo** from **inflammatory**, **oxidative** or **infectious** factors. All this is done in synergy to start the genetic program of embryo development, and start it on its complex pathway, step by step through **organogenesis** and **morphogenesis**.




RegenerAge® Clinic © 2018
www.regenerage.clinic


REGENERAGE®

OOCYTES - MULTIPLE RESPONSIBILITIES


NUCLEAR DNA REPAIR




MORPHOGENESIS




EPIGENETIC MODIFICATIONS




MITOCHONDRIAL DNA REPAIR







TELOMERE CONTROL




ORGANELLE REMODELLING



INFECTIOUS/OXIDATIVE/INFLAMMATORY DEFENSE



MICROENVIRONMENT REGULATION




RegenerAge® Clinic © 2018
www.regenerage.clinic

REGENERAGE®




REPROGRAMMING SYSTEM

REGENERAGE®
CLINIC
INNOVATIVE ANTI-AGING SOLUTIONS



RegenerAge® Clinic © 2018
www.regenerage.clinic

REGENERAGE® SYSTEM



REGENERATIVE THERAPEUTICS

The **RegenerAge® system** has found a novel way to **standardize** this *unique biochemical complex* as a **therapeutic derivative**, thereby generating induction of specific tissues **micro-environments** conducive to **regeneration** and **cellular repair**.

RegenerAge's partner, **Bioquark Inc.®,** is the first company that has taken the step to **export** this **natural & restorative** architecture of the *biochemical regulation* to diseased tissues in humans.

RegenerAge® Clinic © 2018
www.regenerage.clinic

EVIDENCE-BASED MEDICINE



REGENERAGE®
CLINIC
INNOVATIVE ANTI-AGING SOLUTIONS

RegenerAge® Clinic © 2018
www.regenerage.clinic

CASE OF SPINAL CORD INJURY (SCI) PATIENT

35yo male patient suffered from a *complete tear* within the **spinal cord** accompanied by dislocation of the spine due to significant traumatic injury. *Clinical symptoms* were expressed in the *temporary* or *permanent loss* of **cord function** below the injured segments.

RegenerAge Bioquantine® polypeptide was introduced as follows: day 1 to 3 , subcutaneous sensitivity testing at the office without any reactions.

At the hospital we applied via the intrathecal pathway 1ml of pure RegenerAge Bioquantine®, followed by 5 days on intrathecal perfusion by pump.

In addition, a daily SC application has been given to the patient after the hospital release.

INITIAL MRI



POST SURGERY





POST SURGERY



RegenerAge® Clinic © 2018
www.regenerage.clinic

EVIDENCE-BASED MEDICINE





Treatment progress in SCI patient with complete **spinal cord transection** were assessed by MRI imaging and clinical observation of his motor and sensory activity. According American Spinal Injury Association (ASIA) as an ASIA-A class patient (no sensory and no motor functions were preserved below the neurological level segment T12-S1). The patient had been injured after a 9m fall. The initial MRI exams were obtained within 12hrs of injury. Magnetic resonance imaging presents that the patient suffered a *complete tear* within the **spinal cord** accompanied by its **dislocation** due to **significant traumatic injury**.


Clinical symptoms were expressed in the temporary or permanent **loss of cord function** below the injured segments with poor post-SCI prognosis even after the Spinal Cord surgery.

RegenerAge-Bioquantine® was introduced by a Fresenius Pump with a *intrathecal* catheter at S4-S5 due to the anti-gravity effect of the cerebrospinal fluid. During 5 days of perfusion the patient showed notable improvement.

RegenerAge® Clinic © 2018
www.regenerage.clinic


EVIDENCE OF RECOVERY

After a month of treatment the patient **demonstrated considerable improvement** in *sensory* and *strength* ability with moving coordination. He recovered the sensation to urinating and of pain at the lower back and hip, which none of these were noticeable before the application. The patient has subsequently moved from **ASIA-A** to **ASIA-B** *neurological classification of Spinal Cord Injury*.



RegenerAge® Clinic © 2018
www.regenerage.clinic

EVIDENCE-BASED MEDICINE










RegenerAge® Clinic © 2018
www.regenerage.clinic

REGENERAGE®

EVIDENCE-BASED MEDICINE







RegenerAge® Clinic © 2018
www.regenerage.clinic

REGENERAGE®



CASE OF CEREBRAL PALSY PATIENT

11yo patient with Cerebral Palsy due to the medical negligence. Due to a bad performance of an emergency cesarean, the patient was born with an Apgar of 0-0, then after reanimation his cerebral condition moved to an Apgar of 2-3. During his lifetime he develop multiple neurological events, from seizures, meningitis, and spasms with general attacks, lack of breathing and loss of consciousness that would last for hours (a reason why he had to be sedated 85% of his life).

Treatment progress starting **RegenerAge-Bioquantine®** five months ago via SC and IM application in combination with IV MSC's resulted in his quality of life increasing dramatically and for the first time in his life has not been to the ER per the usual routine.

His coordination and his cognition have improved significantly.



RegenerAge® Clinic © 2018
www.regenerage.clinic

REGENERAGE®



CORPORATE VIDEO


RegenerAge® Clinic © 2018

www.regenerage.clinic
info@regenerage.clinic

BUSINESS DEVELOPMENT

REGENERAGE®
CLINIC
INNOVATIVE ANTI-AGING SOLUTIONS

RegenerAge® Clinic © 2018
www.regenerage.clinic



REGENERAGE®

C L I N I C

INNOVATIVE ANTI-AGING SOLUTIONS

CLINICAL DIVISION

RegenerAge® Clinic © 2018
www.regenerage.clinic



NO-OPTION PATIENTS

Major clinical trial gaps currently exist across all therapeutic segments that are responsible for human suffering and death. Cancer is one prime example. As a leading cause of morbidity and mortality worldwide for many decades, today there are approximately 14 million new cases diagnosed each year, with over 8 million cancer related deaths annually (patients who become 'no option'). It is estimated that less than 5% of these patients, take the initiative to participate in any available clinical studies, partially due to the substantial complexity involved with accessing current experimental programs of the industry.

RegenerAge® Clinic © 2018
www.regenerage.clinic

PROCEDURAL MEDICAL TRAVEL

The estimate of the current market size for procedural medical travel, defined by medical travellers who travel across international borders for the purpose of receiving medical care, is in the range of US $40-55 billion, based on approximately eleven million cross-border patients worldwide spending an average of USD 3,500-5,000 per visit, including all medically-related costs, cross-border and local transport, inpatient stay and accommodations. It is estimated that currently over a million Americans travel outside the US for medical annually. As the world population is aging and becoming more affluent at rates that surpass the availability of quality healthcare resources, out-of-pocket medical costs of critical and elective procedures will continue to rise, while nations offering universal care are faced with ever-increasing resource burdens.



RegenerAge® Clinic © 2018
www.regenerage.clinic

THE WORLD ACADEMY OF MEDICAL SCIENCES

RMA REPROGRAMMING MEDICINE ASSOCIATION www.rma.center

ONLINE EDUCATION

Our Clinical Division is focused on providing with Continued Medical Education programs in association with WAMS, The World Academy of Medical Sciences (www.wams.online) and The Reprogramming Medicine Association, providing with cutting edge Regenerative Medicine online courses offered in WAMS' e-Learning platform to accompany our clinical franchise model. Franchisees will have WAMS and RMA accreditation for facilities, academic certification of the medical staff included in the franchise.





REGENERAGE®

INNOVATIVE ANTI-AGING SOLUTIONS

INSTITUTIONAL ALLIANCES DIVISION

RegenerAge® Clinic © 2018
www.regenerage.clinic

EXTENSIVE MEDICAL REACH

The implicit **benefits** will cause an **immediate impact** on the **private medical sector** as our **international medical network** obtains **direct access to BQ-A®** for **clinical use**, as well as to **commercialize** it in **OTC skin care**, **beauty products** and **super foods** market segments, as the company establishes its brand in the digital commerce universe.

As part of **The World Academy of Medical Sciences** (www.wams.online) and **The Reprogramming Medicine Association** (www.rma.center) as well as other medical commercial affiliations, our informative channels have **exponentially grown** with exposure on every **medical events** offered, not only focusing on **clinical development instances,** but also by enabling the RegenerAge® franchising business model across **WAMS' territory**.

THE WORLD ACADEMY OF MEDICAL SCIENCES

RMA REPROGRAMMING MEDICINE ASSOCIATION www.rma.center



RegenerAge® Clinic © 2018
www.regenerage.clinic

REGENERAGE®

SOLID MEDICAL CONNECTIONS

The implicit **benefits** will cause an **immediate impact** on the **private medical sector** as our **international medical network** obtains **direct access to BQ-A®** for **clinical use**, as well as to **commercialize** it in **OTC skin care**, **beauty products** and **super foods** market segments, as the company establishes its brand in the digital commerce universe.

Bioquark Inc.

The World Academy Of Medical Sciences

U.S. Stem Cell Clinic

ICMS International Cellular Medicine Society

A4M American Academy of Anti-Aging Medicine

RMA Reprogramming Medicine Association

Dr. Jois Regenerative & Functional Wisdom

lifeboat foundation Safeguarding Humanity

Hospitales Star Médica

REANIMA Advanced Biosciences

hairlogica Taking Control of Hairloss

what skin needs

Mass Media Dynamics

Stem Cell Fellowship

Sociedad Latinoamericana de Ópera

American Board of Anti-Aging Health Practitioners

DELAPARRA mobilesolutions







COMMERCIAL PRODUCTS

REGENERAGE
CLINIC
INNOVATIVE ANTI-AGING SOLUTIONS







RegenerAge® Clinic © 2018
www.regenerage.clinic

REGENERAGE®

COSMETICS MARKET ANALYSIS

Latin American countries, particularly Brazil and Mexico, are predicted to show **stellar growth in the beauty and personal care market** *over the next five years*, according to a conference at the HBA Global Expo in New York (2010). **Total sales of beauty and personal care products** in Latin American sales were predicted to reach **$80.3bn in 2014.**

The market value, body and foot care in LA (Latin America) would be 86.2bn in 2016. Media Age below is 37 years old. Mexico is the area's second largest market with sales of $17.3bn. Latin America's **top three beauty and personal care categories** are hair care, fragrances and skin care.

Hair care product sales increased from **$11.3bn** from **2012** to **$15.8bn** in 2014.

Source: CBA Associates



RegenerAge® Clinic © 2018
www.regenerage.clinic

REGENERAGE®

INNOVATIVE ANTI-AGING SOLUTIONS

NUTRITION DIVISION



RegenerAge® Clinic © 2018
www.regenerage.clinic



REGENERAGE

NUTRITION MARKET OPPORTUNITY

As we age, **hormonal**, **metabolic** and **nutritional imbalances increase**. **Obesity** has become a global epidemic and GMO products, Processed Food and Fast Food intake are compounding the problem. These issues, combined with a trend towards in increased interest in the fit body / couture world, has placed a major market before us.

BQ-A®'s unique capability to be **transformed** and **stabilized** into **oral formulations**, gives us the opportunity to create a **unique line of super foods and supplements** in combination with other **raw natural/organic ingredients**.

These products will give untapped advantages compared to others as they will be based on the fundamental principles of **Cellular Rejuvenation** and a n**atural resetting of biologic age.**

RegenerAge® Clinic © 2018
www.regenerage.clinic



REGENERAGE®

C L I N I C

INNOVATIVE ANTI-AGING SOLUTIONS

RegenerAge® Clinic © 2018

www.regenerage.clinic
info@regenerage.clinic

SOCIALS